A securities class action lawsuit has been filed against Corcept Therapeutics Incorporated seeking to recover investor losses tied to alleged securities fraud between October 31, 2024 and December 30, 2025. The complaint alleges the company misled investors about FDA feedback on the relacorilant program and the GRACE study design, and about prospects for approval of a relacorilant NDA; investors have until April 21, 2026 to seek appointment as lead plaintiff.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603021600PRIMZONEFULLFEED9664132) on March 02, 2026, and is solely responsible for the information contained therein.